Symbols / BCTX $4.15 -3.94% BriaCell Therapeutics Corp.

Healthcare • Biotechnology • Canada • NCM
BCTX Chart
About

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 30.09M
Enterprise Value -879.26K Income -29.64M Sales —
Book/sh 4.26 Cash/sh 4.12 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -10.64 PEG —
P/S — P/B 0.97 P/C —
EV/EBITDA 0.03 EV/Sales — Quick Ratio 9.39
Current Ratio 10.10 Debt/Eq — LT Debt/Eq —
EPS (ttm) -14.42 EPS next Y -0.39 EPS Growth —
Revenue Growth — Earnings 2025-10-15 19:00 ROA -89.44%
ROE -179.21% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 7.25M
Shs Float 6.41M Short Float 2.01% Short Ratio 0.64
Short Interest — 52W High 98.20 52W Low 3.60
Beta 1.63 Avg Volume 503.94K Volume 21.42K
Target Price — Recom None Prev Close $4.32
Price $4.15 Change -3.94%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$4.40
Latest analyst target
3. DCF / Fair value
$-50.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.40
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-27 main HC Wainwright & Co. Buy → Buy $40
2025-04-22 reit HC Wainwright & Co. Buy → Buy $32
2025-02-03 main HC Wainwright & Co. Buy → Buy $32
2024-12-12 reit HC Wainwright & Co. Buy → Buy $15
2024-12-03 reit HC Wainwright & Co. Buy → Buy $15
2024-10-03 reit HC Wainwright & Co. Buy → Buy $15
2024-09-19 main HC Wainwright & Co. Buy → Buy $15
2024-09-11 reit HC Wainwright & Co. Buy → Buy $18
2024-06-04 reit HC Wainwright & Co. Buy → Buy $18
2024-05-24 reit HC Wainwright & Co. Buy → Buy $18
News
RSS: Latest BCTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-08-25 Bondarenko (Jamieson) Director of Issuer — 10,192 — —
2025-08-25 Del Priore (Giuseppe) Senior Officer of Issuer — 169,551 — —
2025-08-25 Embro-Pantalony (Vaughn) Director of Issuer — 574 — —
2025-08-25 Levin (Gadi) Senior Officer of Issuer — 84,943 — —
2025-08-25 Lopez-Lago (Miguel A) Senior Officer of Issuer — 84,775 — —
2025-08-25 Schmieg (Martin E CPA) Director of Issuer — 34 — —
2025-08-25 Williams (William V) Director of Issuer — 316,957 — —
2025-08-01 Del Priore (Giuseppe) Senior Officer of Issuer — 188,390 — —
2025-08-01 Levin (Gadi) Senior Officer of Issuer — 94,194 — —
2025-08-01 Lopez-Lago (Miguel A) Senior Officer of Issuer — 94,194 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
33.33
+43.22%
23.27
+52.25%
15.29
+119.23%
6.97
Research And Development
27.18
+77.21%
15.34
+91.19%
8.02
+296.93%
2.02
Selling General And Administration
6.15
-22.47%
7.94
+9.19%
7.27
+46.67%
4.96
General And Administrative Expense
6.15
-22.47%
7.94
+9.19%
7.27
+46.67%
4.96
Salaries And Wages
—
—
—
2.15
Other Gand A
6.15
-22.47%
7.94
+9.19%
7.27
+46.67%
4.96
Other Operating Expenses
—
—
-0.00
+8.21%
-0.00
Total Expenses
33.33
+43.22%
23.27
+52.25%
15.29
+119.23%
6.97
Operating Income
-33.33
-43.22%
-23.27
-52.25%
-15.29
-119.23%
-6.97
Total Operating Income As Reported
-33.33
-43.22%
-23.27
-52.22%
-15.29
-119.24%
-6.97
EBITDA
-4.85
+79.16%
-23.26
+13.29%
-26.82
-95.47%
-13.72
Normalized EBITDA
-33.06
-30.51%
-25.34
-67.41%
-15.13
-117.63%
-6.95
Reconciled Depreciation
0.08
+449.39%
0.02
-0.01%
0.02
+0.10%
0.02
EBIT
-4.93
+78.81%
-23.27
+13.29%
-26.84
-95.36%
-13.74
Total Unusual Items
28.22
+1257.46%
2.08
+117.78%
-11.69
-72.70%
-6.77
Total Unusual Items Excluding Goodwill
28.22
+1257.46%
2.08
+117.78%
-11.69
-72.70%
-6.77
Special Income Charges
—
—
0.00
+100.00%
-0.14
Other Special Charges
—
—
—
0.14
Net Income
-4.79
+76.40%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Pretax Income
-4.93
+75.71%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Net Non Operating Interest Income Expense
0.29
-67.68%
0.89
+556.50%
0.14
+280.03%
-0.08
Interest Expense Non Operating
—
0.00
-100.00%
0.00
-98.75%
0.08
Net Interest Income
0.29
-67.68%
0.89
+556.50%
0.14
+280.03%
-0.08
Interest Expense
—
0.00
-100.00%
0.00
-98.75%
0.08
Interest Income Non Operating
0.29
-67.68%
0.89
+551.80%
0.14
+4242.05%
0.00
Interest Income
0.29
-67.68%
0.89
+551.80%
0.14
+4242.05%
0.00
Other Income Expense
28.11
+1252.34%
2.08
+117.78%
-11.69
-72.70%
-6.77
Gain On Sale Of Security
28.22
+1257.46%
2.08
+117.78%
-11.69
-76.39%
-6.63
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-4.93
+75.71%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Net Income From Continuing Operation Net Minority Interest
-4.79
+76.40%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Net Income From Continuing And Discontinued Operation
-4.79
+76.40%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Net Income Continuous Operations
-4.93
+75.71%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Minority Interests
0.14
0.00
—
—
Normalized Income
-33.01
-47.48%
-22.38
-47.73%
-15.15
-114.96%
-7.05
Net Income Common Stockholders
-4.79
+76.40%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Diluted EPS
-43.68
+77.60%
-195.00
+24.86%
-259.50
—
Basic EPS
-43.68
+77.60%
-195.00
+24.86%
-259.50
—
Basic Average Shares
0.11
+5.35%
0.10
+0.81%
0.10
—
Diluted Average Shares
0.11
+5.35%
0.10
+0.81%
0.10
—
Diluted NI Availto Com Stockholders
-4.79
+76.40%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Amortization
—
—
—
0.02
Amortization Of Intangibles Income Statement
—
—
—
0.02
Depreciation Amortization Depletion Income Statement
—
—
—
0.02
Depreciation And Amortization In Income Statement
—
—
—
0.02
Depreciation Income Statement
—
—
—
0.02
Earnings From Equity Interest
-0.11
0.00
—
—
Insurance And Claims
—
—
—
0.32
Rent And Landing Fees
—
—
—
0.01
Rent Expense Supplemental
—
—
—
0.01
Total Other Finance Cost
—
—
11.66
+162.05%
4.45
Line Item Trend 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Total Assets
5.87
-78.38%
27.16
-36.20%
42.58
-26.65%
58.04
Current Assets
3.65
-86.44%
26.95
-36.36%
42.35
-26.73%
57.80
Cash Cash Equivalents And Short Term Investments
0.86
-95.94%
21.25
-48.22%
41.04
-28.33%
57.27
Cash And Cash Equivalents
0.86
-95.94%
21.25
-48.22%
41.04
-28.33%
57.27
Cash Financial
—
—
—
57.27
Receivables
1.37
+90.74%
0.72
+2877.81%
0.02
+91.69%
0.01
Accounts Receivable
—
0.02
-21.70%
0.02
+91.69%
0.01
Other Receivables
1.37
+90.74%
0.72
—
—
Prepaid Assets
1.42
-71.43%
4.98
+288.75%
1.28
+147.82%
0.52
Total Non Current Assets
2.22
+931.48%
0.22
-6.63%
0.23
-6.22%
0.25
Net PPE
0.39
0.00
—
—
Gross PPE
0.46
0.00
—
—
Accumulated Depreciation
-0.07
0.00
—
—
Other Properties
0.46
—
—
—
Goodwill And Other Intangible Assets
0.20
-7.10%
0.22
-6.63%
0.23
-6.22%
0.25
Other Intangible Assets
0.20
-7.10%
0.22
-6.63%
0.23
-6.22%
0.25
Investments And Advances
0.42
+20924400.00%
0.00
+0.00%
0.00
+0.00%
0.00
Long Term Equity Investment
0.42
0.00
—
—
Non Current Prepaid Assets
1.21
0.00
—
—
Total Liabilities Net Minority Interest
8.56
-72.34%
30.94
-4.05%
32.25
+6.18%
30.37
Current Liabilities
7.46
+314.17%
1.80
+91.42%
0.94
+69.02%
0.56
Payables And Accrued Expenses
7.46
+314.17%
1.80
+91.42%
0.94
+69.02%
0.56
Payables
7.17
+538.12%
1.12
+142.56%
0.46
+57.00%
0.30
Accounts Payable
7.17
+538.12%
1.12
+142.56%
0.46
+116.37%
0.21
Other Payable
—
—
—
0.08
Current Accrued Expenses
0.29
-57.15%
0.68
+41.84%
0.48
+82.57%
0.26
Total Non Current Liabilities Net Minority Interest
1.10
-96.24%
29.14
-6.92%
31.31
+5.00%
29.82
Long Term Debt And Capital Lease Obligation
—
—
—
0.03
Long Term Debt
—
—
—
0.03
Stockholders Equity
-2.38
+36.93%
-3.78
-136.57%
10.33
-62.67%
27.67
Common Stock Equity
-2.38
+36.93%
-3.78
-136.57%
10.33
-62.67%
27.67
Capital Stock
72.17
+3.70%
69.59
+6.10%
65.59
+19.74%
54.77
Common Stock
72.17
+3.70%
69.59
+6.10%
65.59
+19.74%
54.77
Share Issued
0.12
+14.41%
0.11
+2.99%
0.10
+1.63%
0.10
Ordinary Shares Number
0.12
+14.41%
0.11
+2.99%
0.10
+1.63%
0.10
Additional Paid In Capital
—
7.42
+41.96%
5.23
+140.03%
2.18
Retained Earnings
-85.44
-5.94%
-80.65
-33.64%
-60.35
-107.09%
-29.14
Gains Losses Not Affecting Retained Earnings
-0.14
+0.00%
-0.14
+0.00%
-0.14
+0.00%
-0.14
Minority Interest
-0.30
0.00
—
—
Other Equity Adjustments
-0.14
+0.00%
-0.14
+0.00%
-0.14
+0.00%
-0.14
Total Equity Gross Minority Interest
-2.68
+28.92%
-3.78
-136.57%
10.33
-62.67%
27.67
Total Capitalization
-2.38
+36.93%
-3.78
-136.57%
10.33
-62.71%
27.70
Working Capital
-3.81
-115.14%
25.15
-39.27%
41.41
-27.66%
57.24
Invested Capital
-2.38
+36.93%
-3.78
-136.57%
10.33
-62.71%
27.70
Total Debt
—
—
—
0.03
Net Tangible Assets
-2.58
+35.32%
-3.99
-139.53%
10.10
-63.18%
27.43
Tangible Book Value
-2.58
+35.32%
-3.99
-139.53%
10.10
-63.18%
27.43
Derivative Product Liabilities
1.10
-96.24%
29.14
-6.92%
31.31
+5.09%
29.79
Investmentsin Subsidiariesat Cost
0.42
0.00
—
—
Other Equity Interest
11.03
+48.66%
7.42
—
18.37
Line Item Trend 2024-07-31 2023-07-31 2022-07-31 2021-07-31
Operating Cash Flow
-24.13
-1.61%
-23.74
-90.20%
-12.48
-61.08%
-7.75
Cash Flow From Continuing Operating Activities
-24.13
-1.61%
-23.74
-90.20%
-12.48
-61.08%
-7.75
Net Income From Continuing Operations
-4.93
+75.71%
-20.30
+24.35%
-26.84
-94.26%
-13.82
Depreciation Amortization Depletion
0.08
+449.39%
0.02
-0.01%
0.02
+0.10%
0.02
Depreciation
0.07
0.00
—
—
Amortization Cash Flow
0.02
+0.00%
0.02
-0.01%
0.02
—
Depreciation And Amortization
0.08
+449.39%
0.02
-0.01%
0.02
+0.10%
0.02
Amortization Of Intangibles
0.02
+0.00%
0.02
-0.01%
0.02
—
Other Non Cash Items
—
—
-0.00
-100.13%
1.88
Stock Based Compensation
1.80
-17.76%
2.19
-28.65%
3.07
+56.21%
1.97
Operating Gains Losses
-28.14
-1227.46%
-2.12
-118.18%
11.66
+159.72%
4.49
Gain Loss On Investment Securities
-28.24
-1232.49%
-2.12
-118.18%
11.66
+162.05%
4.45
Net Foreign Currency Exchange Gain Loss
—
—
—
0.00
Change In Working Capital
7.05
+299.70%
-3.53
-802.65%
-0.39
+82.85%
-2.28
Change In Receivables
-0.73
-14107.23%
0.01
+145.36%
-0.01
-215.98%
0.01
Change In Prepaid Assets
2.13
+148.35%
-4.40
-475.56%
-0.76
-656.61%
-0.10
Change In Payables And Accrued Expense
5.66
+557.82%
0.86
+123.88%
0.38
+117.54%
-2.19
Change In Accrued Expense
-0.39
-293.76%
0.20
+47.94%
0.14
+117.21%
-0.79
Change In Payable
6.05
+815.58%
0.66
+165.07%
0.25
+117.73%
-1.41
Change In Account Payable
6.05
+815.58%
0.66
+165.07%
0.25
+117.73%
-1.41
Investing Cash Flow
-0.68
0.00
—
0.00
Cash Flow From Continuing Investing Activities
-0.68
0.00
—
0.00
Net PPE Purchase And Sale
-0.46
0.00
—
—
Purchase Of PPE
-0.46
0.00
—
—
Capital Expenditure
-0.46
—
—
—
Net Investment Purchase And Sale
—
—
—
0.00
Net Business Purchase And Sale
-0.23
0.00
—
—
Purchase Of Business
-0.23
0.00
—
—
Financing Cash Flow
4.42
+11.75%
3.95
+205.65%
-3.74
-105.76%
65.00
Cash Flow From Continuing Financing Activities
4.42
+11.75%
3.95
+205.65%
-3.74
-105.76%
65.00
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.33
Issuance Of Debt
—
—
0.00
-100.00%
0.22
Repayment Of Debt
—
—
0.00
+100.00%
-0.55
Long Term Debt Issuance
—
—
—
0.22
Long Term Debt Payments
—
—
—
-0.31
Net Long Term Debt Issuance
—
—
—
-0.09
Short Term Debt Issuance
—
—
0.00
-100.00%
0.22
Short Term Debt Payments
—
—
0.00
+100.00%
-0.55
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-0.33
Net Common Stock Issuance
4.42
+11.79%
3.95
+138.86%
-10.17
-119.70%
51.62
Common Stock Payments
0.00
+100.00%
-0.05
+99.54%
-10.17
0.00
Repurchase Of Capital Stock
0.00
+100.00%
-0.05
+99.54%
-10.17
0.00
Proceeds From Stock Option Exercised
0.00
-100.00%
0.00
-99.98%
6.51
-52.50%
13.71
Net Other Financing Charges
—
—
-0.08
—
Changes In Cash
-20.39
-3.02%
-19.79
-21.96%
-16.23
-128.35%
57.25
Effect Of Exchange Rate Changes
—
—
—
0.00
Beginning Cash Position
21.25
-48.22%
41.04
-28.33%
57.27
+269412.38%
0.02
End Cash Position
0.86
-95.94%
21.25
-48.22%
41.04
-28.33%
57.27
Free Cash Flow
-24.58
-3.53%
-23.74
-90.20%
-12.48
-61.08%
-7.75
Common Stock Issuance
4.42
+10.47%
4.00
0.00
-100.00%
51.62
Earnings Losses From Equity Investments
0.11
0.00
—
—
Issuance Of Capital Stock
4.42
+10.47%
4.00
0.00
-100.00%
51.62
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category